This inventor holds 2 USPTO granted patents. Top assignee: University of Virginia Patent Foundation. Active years: 2016-2017.
Location History:
- Charlottesville, VA (US) (2016)
- Crozet, VA (US) (2017)
Company Filing History:
Years Active: 2016-2017
Title: Innovations in Tissue Engineering by Mary J Laughlin
Introduction
Mary J Laughlin is a prominent inventor based in Crozet, VA (US). She has made significant contributions to the field of tissue engineering and cell-based therapies. With a total of 2 patents, her work focuses on advancing medical treatments through innovative methodologies.
Latest Patents
Her latest patents include "Compositions and methods for tissue engineering and cell-based therapies." This invention discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists, as well as regulators of chemokine receptors. In an in vivo ischemic model, S1P/S1P activation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs), which have the potential to increase microvascular remodeling. The expression of S1P on marrow-derived cells was essential for this remodeling. Concurrent systemic S1P and CXCR4 antagonism mobilized hematopoietic stem cells (HSCs) capable of engrafting and repopulating blood cells. Pre-treatment of donor HSCs with FTY720 increased their homing toward SDF-1 and improved engraftment in marrow. Additionally, FTY720-coated bone allografts, coupled with systemic administration of VPC01091, enhanced bone allograft integration and new bone formation in bone defects. MSCs pre-treated with FTY720 exhibited increased migration toward SDF-1, a CXCR4+ ligand. The results demonstrate that S1P plays a powerful role in pharmacological marrow-derived stem cell mobilization and recruitment.
Another significant patent is "Compositions and methods for CXCR4 signaling and umbilical cord blood stem cell engraftment." This invention enhances engraftment by co-infusing at least two partially HLA matched umbilical cord blood (UCB) units. It provides for positive C3a mediated priming on responsiveness to doses of SDF-1 and C3a induced incorporation of CXCR4 in membranes in HSC and progenitors. The invention also enhances the homing of UCB HSC and progenitors via the SDF-1/CXCR4 pathway, indicating that C3a and LL-37 are useful for this method. Furthermore, it discloses that fragments of C3a (e.g., des-Arg) are effective in enhancing